Amiodarone

Overview

Amiodarone (Cordarone®, Nexterone®, Pacerone®) is a class III antiarrhythmic agent used in dogs for the management of serious and refractory cardiac arrhythmias when other antiarrhythmic therapies are ineffective or contraindicated. Because of its potential for toxicity and limited veterinary experience, its use in small animals is considered extra-label and requires careful case selection and close monitoring.

In dogs, amiodarone is most often reserved for arrhythmias associated with systolic myocardial dysfunction, including atrial fibrillation and certain ventricular or supraventricular tachyarrhythmias. Clinical response may be delayed, with therapeutic effects developing over several days to weeks due to extensive tissue distribution and accumulation.

Mechanism of Action (MOA): Amiodarone primarily blocks potassium channels, prolonging the myocardial action potential duration and refractory period. In addition, it exhibits properties of multiple antiarrhythmic classes by blocking sodium and calcium channels and exerting noncompetitive beta-adrenergic antagonism. These combined effects reduce abnormal automaticity and re-entrant arrhythmias.

Amiodarone is highly lipophilic, extensively distributed into tissues, and metabolized hepatically to an active metabolite (desethylamiodarone). Its complex pharmacokinetics and broad spectrum of systemic effects necessitate cautious dosing, awareness of drug interactions, and routine clinical and laboratory monitoring in dogs.

Indications

Amiodarone is used in dogs as a second- or third-line antiarrhythmic agent when more commonly used and less toxic therapies are ineffective or contraindicated. Because of its potential for serious adverse effects and limited veterinary experience, its use is restricted to situations in which the expected clinical benefit outweighs the risks.

• Atrial fibrillation (dogs): Used for cardioversion from atrial fibrillation to sinus rhythm, particularly in dogs with systolic myocardial dysfunction or refractory disease.
• Refractory ventricular arrhythmias (dogs): May be considered for life-threatening ventricular tachyarrhythmias that do not respond adequately to standard antiarrhythmic agents.
• Supraventricular tachyarrhythmias (dogs): Used in selected cases of supraventricular tachycardia or atrial flutter when conventional therapies fail.
• Arrhythmias associated with systolic dysfunction (dogs): Considered when arrhythmias occur in the setting of myocardial disease and other antiarrhythmic drugs are ineffective or poorly tolerated.
• Trypanosoma cruzi infection (dogs, adjunctive use): When combined with itraconazole, amiodarone has been shown to reduce mortality and clinical signs associated with Chagas disease.

Use in cats: Clinical experience with amiodarone in cats is extremely limited, and clear therapeutic indications have not been established. Routine use in cats is not recommended due to the lack of safety and efficacy data.

Dosage (Reference)

Dog

Dosage regimens for amiodarone in dogs are not well standardized and are based on limited clinical experience and retrospective studies. Because of its complex pharmacokinetics and potential toxicity, therapy should be initiated cautiously, preferably in a monitored clinical setting.

Cat

There are no well-established dosage recommendations for amiodarone in cats. Published clinical experience is extremely limited, and safety and efficacy have not been clearly defined.

Warnings & Precautions

Amiodarone is a potent antiarrhythmic drug with a narrow margin of safety and limited clinical experience in small animals. Its use in dogs (and rarely cats) should be reserved for carefully selected cases and requires close clinical, electrocardiographic, and laboratory monitoring.

• Cardiogenic shock and severe bradyarrhythmias: Contraindicated in patients with cardiogenic shock, severe sinus bradycardia, sinus node dysfunction, or second- or third-degree atrioventricular block unless a pacemaker is present.
• Iodine hypersensitivity: Contraindicated in animals with known hypersensitivity to iodine or iodinated compounds.
• Thyroid dysfunction: Use with caution in dogs with pre-existing thyroid disease. Amiodarone inhibits peripheral conversion of T4 to T3 and may induce hypothyroidism or, less commonly, hyperthyroidism.
• Hepatic disease: Use cautiously in patients with liver disease. Hepatotoxicity has been reported in dogs and may occur before clinical signs are evident; routine monitoring of liver enzymes and bilirubin is recommended.
• Breed considerations: Doberman Pinschers with ventricular arrhythmias and preclinical systolic dysfunction may be at increased risk for hepatic and gastrointestinal toxicity; use cautiously in this breed.
• Cardiac effects: May worsen or induce bradycardia, hypotension, or conduction disturbances; continuous ECG monitoring is recommended during IV administration.
• IV formulation reactions: IV formulations containing polysorbate 80 have been associated with histamine-mediated reactions in dogs (eg, hypotension, edema, pruritus). Polysorbate-80–free formulations are preferred when available.
• Delayed onset and long persistence: Due to extensive tissue accumulation and long half-life, adverse effects may persist for weeks after dose reduction or discontinuation.
• Geriatric and debilitated patients: May be more sensitive to adverse effects; initiate therapy at the lowest effective dose and monitor closely.
• Use in cats: Clinical data in cats are extremely limited. Use is generally not recommended due to unknown safety and efficacy.

Drug Interactions

Amiodarone has a high potential for clinically significant drug interactions due to its effects on cardiac conduction, hepatic metabolism, and drug transport systems. Careful review of all concurrent medications and close monitoring are essential when amiodarone is prescribed to dogs (and rarely cats).

• Beta-adrenergic blockers (e.g., atenolol, metoprolol, propranolol): Additive effects on heart rate and AV conduction may result in severe bradycardia or heart block.
• Calcium channel blockers (e.g., diltiazem, verapamil, amlodipine): Increased risk of bradycardia, AV block, sinus arrest, and hypotension.
• Digoxin: Amiodarone can increase serum digoxin concentrations and enhance its pharmacologic effects, increasing the risk of bradycardia and digoxin toxicity.
• Other antiarrhythmic drugs (e.g., procainamide, quinidine, sotalol): Additive electrophysiologic effects and QT prolongation may increase the risk of life-threatening arrhythmias.
• QT-prolonging drugs: Concurrent use with drugs that prolong the QT interval (eg, certain macrolide antibiotics, azole antifungals, cisapride) may increase the risk of ventricular arrhythmias and should be avoided when possible.
• Azole antifungals (e.g., itraconazole, ketoconazole): May increase amiodarone concentrations and QT prolongation risk; close monitoring is required. Itraconazole has been intentionally combined with amiodarone in specific canine protocols under strict supervision.
• Macrolide antibiotics (e.g., erythromycin, azithromycin): Increased risk of QT prolongation and arrhythmias.
• Opioids (e.g., fentanyl, morphine, methadone, buprenorphine): May potentiate bradycardia and hypotension; careful cardiovascular monitoring is advised.
• Warfarin: Amiodarone may increase anticoagulant effects; although rarely used in veterinary patients, bleeding risk should be considered if combined.
• Theophylline: Amiodarone may reduce theophylline metabolism, increasing the risk of theophylline toxicity.
• General anesthetics (e.g., isoflurane, propofol): Increased risk of hypotension, bradycardia, and conduction abnormalities during anesthesia.
• Cholestyramine: May decrease amiodarone absorption and serum concentrations.
• Rifampin: May reduce amiodarone concentrations due to enzyme induction, potentially decreasing efficacy.

Side Effects & Overdose

Side Effects

Adverse effects associated with amiodarone in dogs (and rarely cats) are relatively common and may be dose-dependent, cumulative, or delayed due to the drug’s long tissue half-life. Gastrointestinal and hepatic effects are the most frequently reported in small animal patients.

• Gastrointestinal disturbances: The most common adverse effects in dogs, including anorexia, nausea, vomiting, and diarrhea.
• Hepatotoxicity: Elevations in liver enzymes and bilirubin have been reported. Hepatic injury may occur before clinical signs are evident; dose reduction or discontinuation is required if hepatopathy develops.
• Bradycardia and conduction disturbances: Sinus bradycardia, AV block, or worsening of pre-existing bradyarrhythmias may occur.
• Bone marrow effects: Neutropenia and thrombocytopenia have been reported in dogs.
• Ocular effects: Corneal deposits (keratopathy) may be observed; these are typically non-painful and reversible.
• Immune-mediated effects: Regenerative anemia and positive Coombs test results have been documented.
• Dermatologic and hypersensitivity reactions (IV use): Pruritus, erythema, edema, hives, agitation, tachypnea, and hypotension have been reported, particularly with IV formulations containing polysorbate 80.
• Decreased myocardial contractility: Observed at higher IV doses under experimental conditions.
• Thyroid dysfunction: Amiodarone may alter thyroid hormone metabolism and can exacerbate or induce hypo- or hyperthyroidism, especially with long-term therapy.

Overdose

Clinical experience with amiodarone overdose in dogs and cats is limited. Due to its pharmacokinetics and tissue accumulation, toxic effects may be prolonged and difficult to reverse.

• Cardiovascular effects: Severe bradycardia, hypotension, atrioventricular block, cardiogenic shock, and worsening arrhythmias.
• Hepatic toxicity: Marked elevations in liver enzymes and acute hepatopathy may occur.
• Neurologic signs: Lethargy, weakness, or collapse secondary to cardiovascular compromise.
• Management: There is no specific antidote. Treatment is supportive and includes intensive cardiovascular monitoring, management of hypotension and bradycardia, and discontinuation of the drug.
• Supportive care: Bradycardia may require beta-agonists or pacing; hypotension may require IV fluids and vasopressors or positive inotropes as indicated.
• Dialysis: Neither amiodarone nor its active metabolite is effectively removed by hemodialysis.

Key Notes

Practical clinical points to guide the safe and rational use of amiodarone in dogs and cats, focusing on situations where benefits may outweigh potential risks:

• Reserve use only: Amiodarone should be considered a second- or third-line antiarrhythmic in dogs when more commonly used agents fail or are contraindicated.
• Delayed onset of action: Clinical antiarrhythmic effects may take several days to weeks to become evident, particularly with oral therapy.
• Long tissue persistence: Due to extensive tissue accumulation, adverse effects may persist even after dose reduction or drug discontinuation.
• Loading strategies: Oral loading doses are often used to achieve therapeutic effect more rapidly, but increase the risk of adverse effects and require close monitoring.
• Monitoring is essential: Regular evaluation of ECG, liver enzymes, bilirubin, CBC, and thyroid function is critical during therapy.
• IV formulation selection: Polysorbate 80–free formulations are preferred for IV administration to reduce the risk of histamine-mediated reactions.
• Breed considerations: Doberman Pinschers with preclinical systolic dysfunction may be at increased risk for toxicity and require extra caution.
• Client communication: Owners should be informed that this drug is used infrequently, has a narrow safety margin, and requires strict adherence to follow-up and monitoring plans.